Q4 2025 Carlsmed Inc Earnings Call Transcript
Key Points
- Carlsmed Inc (CARL) achieved significant revenue growth in 2025, with an 86% year-over-year increase, reaching $50.5 million.
- The company successfully completed its initial public offering in July 2025, raising over $100 million to support innovation and expansion.
- Carlsmed Inc (CARL) reported impressive gross margins of 75.3% for the full year and 76.5% for the fourth quarter, indicating strong operational efficiency.
- The company's digital production system advancements have reduced lead times for their products to six business days, enhancing productivity.
- Carlsmed Inc (CARL) has shown strong market adoption with 101 new surgeon users added in 2025, reflecting rapid clinical adoption and demand for their innovative solutions.
- Carlsmed Inc (CARL) reported a GAAP net loss of $29.6 million for 2025, an increase from the $24.3 million net loss in 2024.
- Total operating expenses rose significantly to $68.6 million in 2025, driven by increased R&D, sales, and marketing expenses.
- The company's EBITDA adjusted for stock-based compensation was a negative $28.4 million for 2025, indicating ongoing financial challenges.
- Despite revenue growth, Carlsmed Inc (CARL) faces pressure to achieve cash flow breakeven, with substantial investments required for scaling operations.
- The cervical spine fusion market launch is still in early stages, with potential downward pressure on average selling prices due to different reimbursement profiles.
Ladies and gentlemen, thank you for standing by, and welcome to the Carlsmed fourth-quarter and full year 2025 earnings conference call. (Operator Instructions)
I would now like to turn the conference over to your first today, Caroline Corner, Investor Relations. Please go ahead, Caroline.
Thank you, operator. Welcome to Carlsmed's fourth-quarter and full year 2025 earnings call. Joining me on today's call are Mike Cordonnier, Chief Executive Officer and Chairman; and Leo Greenstein, Chief Financial Officer.
Before we begin, I would like to caution that comments made during this call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements made on this call that do not relate to matters of historical facts should be considered forward-looking statements, including statements regarding the market in which Carlsmed operates, trends, expectations and demand for Carlsmed's products and Carlsmed's expected financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
